Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)

Denali Therapeutics (DNLI) has 5 years of Receivables - Other data on file, last reported at $357000.0 in Q2 2022.

• Quarterly Receivables - Other fell 77.22% year-over-year to $357000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $357000.0 (down 77.22% YoY) and the FY2021 annual result came in at $1.2 million, down 78.39% from the prior year.
• Receivables - Other retreated to $357000.0 in Q2 2022 per DNLI's latest filing, from $1.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $5.7 million in Q4 2020 and bottomed at $357000.0 in Q2 2022.
• The 4-year median for Receivables - Other is $1.2 million (2021), against an average of $2.0 million.
• The widest annual swing landed in 2018, when Receivables - Other surged 154.74%; it then slumped 78.39% in 2021.
• Tracing DNLI's Receivables - Other over 4 years: stood at $1.2 million in 2018, then surged by 380.03% to $5.7 million in 2020, then tumbled by 78.39% to $1.2 million in 2021, then slumped by 70.88% to $357000.0 in 2022.
• Per Business Quant, the three latest DNLI Receivables - Other figures stand at $357000.0 (Q2 2022), $1.2 million (Q4 2021), and $1.2 million (Q3 2021).

Peer Comparison